Table 1.

Baseline Characteristics of the 31 Study Patients^a,b,c

Variable	Value
Age (y)	59.7±16.7
Female	13 (41.9)
Hypercoagulable states
Myeloproliferative disorders	5 (16.1)
Lupus anticoagulant positive	3 (9.7)
Factor V Leiden heterozygote	2 (6.4)
Klippel-Trenaunay syndrome	1 (3.2)
Lupus anticoagulant and factor V Leiden heterozygote	1 (3.2)
ANCA vasculitis	1 (3.2)
Thoracic outlet syndrome	1 (3.2)
Prior pulmonary endarterectomy	5 (16.1)
6-Minute walk distance (m)	402 (311-439)
NT-proBNP (pg/mL)	312 (71-882)
$\dot{\text{V}}$o2max (mL/kg/min)	14.9 (12.6-19.9)
VE/$\dot{\text{V}}$co2 nadir	38 (31-46)
NYHA class
II	9 (29.0)
III	22 (71.0)
Medications
PAH-targeted therapies
Riociguat	22 (71.0)
Sildenafil	1 (3.2)
Tadalafil	1 (3.2)
Bosentan	1 (3.2)
Macitentan	3 (9.7)
Treprostinil (inhaled)	1 (3.2)
Antiplatelet/anticoagulant
Aspirind	21 (67.7)
Warfarin	21 (67.7)
Novel oral anticoagulants	10 (32.3)
Others
Loop diuretic	5 (16.1)
Spironolactone	3 (9.7)

^aANCA = antineutrophil cytoplasmic antibody, NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association; PAH = pulmonary arterial hypertension; VE/$\dot{\text{V}}$co₂ = minute ventilation/carbon dioxide production; $\dot{\text{V}}$o_2max = maximum oxygen consumption.

^bData are presented as mean ± SD, No. (percentage) of patients, or median (interquartile range).

^cSI conversion factors: To convert NT-proBNP values to ng/L, multiply by 1.0.

^dOne patient was taking 325 mg of acetylsalicylic acid, and the rest received 81 mg.